Assessment of asthma control and its impact on optimal treatment strategy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 62, Issue 6, 2007, Pages 611-619

  Lundback, B ^a   Dahl, R ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Asthma control; Exacerbations; Hyperresponsiveness ; Inhaled corticosteroids; Long acting beta2 agonists

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; SALMETEROL; TERBUTALINE;

ADD ON THERAPY; AIRWAY; ALLERGIC ASTHMA; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE COMPARISON; HUMAN; INFLAMMATION; LOW DRUG DOSE; LUNG FUNCTION; MAINTENANCE THERAPY; MEDICAL ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYMPTOM; TISSUE REGENERATION; TREATMENT DURATION;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS;

EID: 34248548290     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2007.01399.x     Document Type: Review

References (77)

1. European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996 9 : 687 695.
2. Chinn S, Burney P, Jarvis D, Luczynska C. Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1997 10 : 2495 2501.
3. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC. Lancet 1998 351 : 1225 1232.
4. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Available at: http://www.ginasthma.com/Guidelineitem. Accessed 26th February 2007.
5. Grize L, Gassner M, Wuthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH et al. Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001. Allergy 2006 61 : 556 562.
6. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999; the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000 16 : 802 807.
7. Rabe KF, Adachi M, Lai CKW, Soriano JB, Vermeire PA, Weiss KB et al. Worldwide severity and control of asthma in children and adults: the global Asthma Insights and Reality surveys. J Allergy Clin Immunol 2004 114 : 40 47.
8. Turner MO, Noertjojo K, Vedal S, Bai T, Crump S, Fitzgerald JM. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998 157 : 1804 1809.
9. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991 325 : 388 392.
10. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Nonspecific Lung Disease Study Group. Am Rev Respir Dis 1992 146 : 547 554.
11. Kerrebijn KF, van Essen-Zandvliet EE, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987 79 : 653 659.
12. Stoloff S, Poinsett-Holmes K, Dorinsky PM. Combination therapy with inhaled long-acting β2-agonists and inhaled corticosteroids. A paradigm shift in asthma management. Pharmacotherapy 2002 22 : 212 226.
13. British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 2003 58 (Suppl. I): 98 99.
14. National Asthma Education and Prevention Program (NAEPP) Expert Panel Report: Guidelines for the diagnosis and management of asthma - update on selected topics 2002. National Heart, Lung and Blood Institute. NIH Publication No. 02-5075.
15. Geijer RMM, van Hensbergen W, Bottema BJAM, van Schayck CP, Sachs APE, Smeele IJM et al. NHG Practice Guideline 'Adult asthma: treatment'. Available at: http//www.nhg.artsennet.nl/upload/104/guidelines2/E27b.htm. Last updated 2004. Last accessed 15 October 2004.
16. Bateman E, Boushey H, Bousquet J, Busse W, Clark T, Pauwels R et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study Am J Respir Crit Care Med 2004 170 : 836 844.
17. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005 171 : 129 136.
18. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006 368 : 744 753.
19. Humbert M, Holgate S, Boulet L-P, Bousquet J. Asthma control or severity: that is the question. Allergy 2007 62 : 95 101.
20. Chipps BE, Spahn JD. What are the determinates of asthma control? J Asthma 2006 43 : 567 572.
21. Revicki D, Weiss KB. Clinical assessment of asthma symptom control: review of current assessment instruments. J Asthma 2006 43 : 481 487.
22. Yawn BP, Brenneman SK, Allen-Ramey FC, Cabana MD, Markson LE. Assessment of asthma severity and asthma control in children. Pediatrics 2006 118 : 322 329.
23. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999 14 : 902 907.
24. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005 99 : 553 558.
25. Juniper EF, Bousquet J, Abetz L, Bateman ED, GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006 100 : 616 621.
26. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004 113 : 59 65.
27. Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006 117 : 549 556.
28. Wallenstein GV, Carranza-Rosenzweig J, Kosinski M, Blaisdell-Gross B, Gajria K, Jhingran P. A psychometric comparison of three patient-based measures of asthma control. Curr Med Res Opin 2007 23 : 369 377.
29. Leblanc A, Robichaud P, Lacasse Y, Boulet LP. Quantification of asthma control: validation of the Asthma Control Scoring System. Allergy 2007 62 : 120 125.
30. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004 59 : 94 99.
31. Kips J. Managing a variable disease. Pulm Pharmacol Ther 2002 15 : 485 490.
32. Barnes PJ. Poorly perceived asthma. Thorax 1992 47 : 408 409.
33. Rietveld S. Symptom perception in asthma: a multidisciplinary review. J Asthma 1998 35 : 137 146.
34. Killian KJ, Watson R, Otis J, St Amand TA, O'Byrne PM. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med 2000 162 : 490 496.
35. Turcotte H, Corbeil F, Boulet LP. Perception of breathlessness during bronchoconstriction induced by antigen, exercise and histamine challenges. Thorax 1990 45 : 914 918.
36. Barnes PJ. Blunted perception and death from asthma. N Engl J Med 1994 330 : 1383 1384.
37. Jones PW. Breathlessness perception in airways obstruction. Eur Respir J 1992 5 : 1035 1036.
38. Janson S, Reed ML. Patients' perceptions of asthma control and impact on attitudes and self-management. J Asthma 2000 37 : 625 640.
39. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002 110 : 58 64.
40. Lai CK, de Guia TS, Kim YY, Kuo SH, Mukhopadhyay A, Soriano JB et al. Asthma control in Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific study. J Allergy Clin Immunol 2003 111 : 263 268.
41. Laforest L, Van Ganse E, Devouassoux G, Chretin S, Bauguil G, Pacheco Y et al. Quality of asthma care: results from a community pharmacy based survey. Allergy 2005 60 : 1505 1510.
42. Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists. Curr Pharm Des 2006 12 : 3261 3279.
43. Jarjour NN, Wilson SJ, Koenig SM, Laviolette M, Moore WC, Davis WB et al. Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. J Allergy Clin Immunol 2006 118 : 44 52.
44. Haahtela T, Tamminen K, Malmberg LP, Zetterström O, Karjalainen J, Ylä-Outinen H et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. Eur Respir J 2006 28 : 748 755.
45. Pedersen S. Budesonide plus formoterol for reliever therapy in asthma. Lancet 2006 368 : 707 708.
46. Woolcock AJ. What are the important questions in the treatment of asthma? Clin Exp Allergy Rev 2001 1 : 62 64.
47. Reddel HK, Jenkins CR, Marks GB, Ware SI, Xuan W, Salome CM et al. Optimal asthma control, starting with high doses of budesonide. Eur Respir J 2000 16 : 226 235.
48. Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002 57 : 309 316.
49. Lundbäck B, Rönmark E, Lindberg A, Jonsson AC, Larsson LG, Petavy F et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med 2006 100 : 2 10.
50. Lundbäck B, Rönmark E, Lindberg A, Jonsson A-C, Larsson L-G, Gor D et al. Sustained asthma control can eliminate airway hyperreactivity: a 3 year study. Eur Respir J 2006 28 (Suppl. 50 218s.
51. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002 360 : 1715 1721.
52. Jayaram L, Pizzichini MM, Cook RJ et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006 27 : 483 494.
53. Dahl R, Johansson S-Å. Importance of duration of treatment with inhaled budesonide on the immediate and late bronchial reaction. Eur J Respir Dis Suppl 1982 122 : 167 175.
54. Henriksen JM, Dahl R. Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma. Am Rev Respir Dis 1983 128 : 993 997.
55. Dahl R, Larsen BB, Venge P. Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med 2002 96 : 432 438.
56. Pedersen B, Dahl R, Karlstrom R, Peterson CG, Venge P. Eosinophil and neutrophil activity in asthma in a one year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med 1996 153 : 1519 1529.
57. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003 361 : 1071 1076.
58. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997 337 : 1405 1411.
59. Sont JK, Willems LNA, Bel EH, van Kriekan HJM, Vandenbrouchke JP, Sterk PJ et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999 159 : 1043 1051.
60. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001 164 : 1376 1381.
61. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998 53 : 91 95.
62. Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001 164 : 738 743.
63. Nordvall SL, Janson C, Kalm-Stephens P, Foucard T, Toren K, Alving K. Exhaled nitric oxide in a population-based study of asthma and allergy in schoolchildren. Allergy 2005 60 : 469 475.
64. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005 352 : 2163 2173.
65. de Kluijver J, Evertse CE, Schrumpf JA, van der Veen H, Zwindrman AH, Hiemstra PS et al. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma. Am J Respir Crit Care Med 2002 166 : 294 300.
66. Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Bouschey HA, Chincilli VM et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005 115 : 720 727.
67. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004 363 : 271 275.
68. Fitzgerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J et al. Doubling the dose of budesonide vs maintenance treatment in asthma exacerbations. Thorax 2004 59 : 550 556.
69. Busse WW, Lemanske RF. Management of asthma exacerbations. Thorax 2004 59 : 545 546.
70. Foresi A, Morelli MC, Catena E, on behalf of the Italian Study Group. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000 117 : 440 446.
71. Reddel HK, Barnes DJ, Exacerbation Advisory Panel. Pharmacological strategies for self-management of asthma exacerbations. Eur Respir J 2006 28 : 182 199.
72. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000 320 : 1368 1373.
73. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodelling. Am J Respir Crit Care Med 2000 161 : 1720 1745.
74. ten Brinke A, Sterk PJ, Masclee AA et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005 26 : 812 818.
75. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. BMJ 2003 326 : 1115 1120.
76. Reddel HK, Vincent SD, Civitico J. The need for standardisation of peak flow charts. Thorax 2005 60 : 164 167.
77. Lenoir M, Williamson A, Stanford RH, Stempel DA. Assessment of asthma control in a general population of asthmatics. Curr Med Res Opin 2006 22 : 17 22.